Wonvas-Gold Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (10 mg), and Clopidogrel (75 mg), designed to provide comprehensive cardiovascular protection. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 synthesis and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) levels, contributing to the stabilization of atherosclerotic plaques and reduction of cardiovascular risk. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP P2Y12 receptor on platelet surfaces, further preventing platelet activation and aggregation. The synergistic action of these three agents makes Wonvas-Gold Capsule suitable for secondary prevention of atherosclerotic cardiovascular events, including myocardial infarction, stroke, and peripheral arterial disease, particularly in patients with established coronary artery disease or high cardiovascular risk profiles. This combination therapy should be administered under strict medical supervision due to potential risks such as bleeding complications and hepatic or renal impairment. Regular monitoring of lipid profiles, liver function tests, and complete blood counts is recommended to ensure therapeutic efficacy and safety. Wonvas-Gold Capsule is contraindicated in patients with active bleeding, hypersensitivity to any component, or severe hepatic dysfunction.